Could Penumbra Inc (NYSE:PEN) Skyrocket? The Stock Had Too Little Sellers

August 9, 2018 - By Mark Babin

Penumbra, Inc. (NYSE:PEN) Logo

The stock of Penumbra Inc (NYSE:PEN) registered a decrease of 4.51% in short interest. PEN’s total short interest was 2.06 million shares in August as published by FINRA. Its down 4.51% from 2.16 million shares, reported previously. With 162,400 shares average volume, it will take short sellers 13 days to cover their PEN’s short positions. The short interest to Penumbra Inc’s float is 6.77%.

It closed at $124.65 lastly. It is down 85.64% since August 9, 2017 and is uptrending. It has outperformed by 73.07% the S&P500.

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company has market cap of $4.27 billion. The firm offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, PX SLIM, and Velocity brands; aspiration based thrombectomy systems and accessory devices under the Penumbra System brand; and revascularization device for mechanical thrombectomy under the 3D brand. It has a 345.29 P/E ratio. It also provides neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands; and neurovascular stents for stent-assisted coiling in large and wide-neck aneurysms under the LIBERTY Stent brand.

More news for Penumbra, Inc. (NYSE:PEN) were recently published by: Benzinga.com, which released: “85 Biggest Movers From Yesterday” on August 09, 2018. Benzinga.com‘s article titled: “68 Stocks Moving In Wednesday’s Mid-Day Session” and published on August 08, 2018 is yet another important article.

Penumbra, Inc. (NYSE:PEN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.